This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Ginsburg KB , Cher ML , Kutikov A , Morgan TM
Pathologically Node-Positive Prostate Cancer Casting for Cure When the Die Is Cast?
Cancer J. 2020 Jan-Feb;26(1) :58-63
PMID: 31977387 URL: https://www.ncbi.nlm.nih.gov/pubmed/31977387
AbstractThe postoperative management of men with lymph node involved prostate cancer (pN+) remains a challenge as there is a general lack of randomized trial data and a range of management strategies. Retrospective studies suggest a variable clinic course for patients with pN+ prostate cancer. Some men progress rapidly to metastatic disease despite further therapies, whereas other men can have a period of prolonged quiescence without adjuvant androgen deprivation therapy (ADT) or radiation therapy (RT). For men who have undergone radical prostatectomy, randomized trial data indicate that the addition of ADT in pN+ disease extends metastasis-free, prostate cancer-specific, and overall survival. Additional retrospective studies suggest that adding RT is potentially beneficial in this setting, improving overall and cancer-specific survival especially in men with certain pathologic parameters. Conversely, men with lower disease burden in their lymph nodes have longer times to progression and may be candidates for observation and salvage therapy as opposed to adjuvant ADT/RT.
NotesGinsburg, Kevin B. Cher, Michael L. Kutikov, Alexander Morgan, Todd M. 1540-336x